Head to Head Survey: Perspective Therapeutics (NYSE:CATX) versus Biostage (OTCMKTS:BSTG)

Biostage (OTCMKTS:BSTG) and Perspective Therapeutics (NYSE:CATX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, risk, analyst recommendations, profitability, institutional ownership, valuation and earnings.

Analyst Ratings

This is a breakdown of current ratings and target prices for Biostage and Perspective Therapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biostage	0	0	0	0	0.00
Perspective Therapeutics	0	1	7	3	3.18

Perspective Therapeutics has a consensus target price of $12.75, indicating a potential upside of 451.95%. Given Perspective Therapeutics’ stronger consensus rating and higher possible upside, analysts clearly believe Perspective Therapeutics is more favorable than Biostage.

Valuation & Earnings

This table compares Biostage and Perspective Therapeutics”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biostage	N/A	N/A	-$6.07 million	($0.58)	-7.67
Perspective Therapeutics	$1.43 million	119.62	-$46.51 million	N/A	N/A

Biostage has higher earnings, but lower revenue than Perspective Therapeutics.

Profitability

This table compares Biostage and Perspective Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Biostage	N/A	N/A	-174.43%
Perspective Therapeutics	-4,096.66%	-27.40%	-23.16%

Insider & Institutional Ownership

54.7% of Perspective Therapeutics shares are owned by institutional investors. 15.3% of Biostage shares are owned by insiders. Comparatively, 3.5% of Perspective Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Volatility and Risk

Biostage has a beta of -1.02, suggesting that its stock price is 202% less volatile than the S&P 500. Comparatively, Perspective Therapeutics has a beta of 1.2, suggesting that its stock price is 20% more volatile than the S&P 500.

Summary

Perspective Therapeutics beats Biostage on 8 of the 12 factors compared between the two stocks.

About Biostage

Biostage, Inc., a biotechnology company, offers products to cure patients of cancers, injuries, and birth defects of the gastro-intestinal tract and the airways. The company's pipeline includes organ-regeneration technology for the repair or replacement of diseased or damaged organs, as well as product candidates to treat cancer, injury, and birth defects of the bronchus. Its lead product candidate is Biostage Esophageal Implant for the treatment of severe esophageal disease. The company was formerly known as Harvard Apparatus Regenerative Technology, Inc. and changed its name to Biostage, Inc. in March 2016. Biostage, Inc. was founded in 2009 and is headquartered in Holliston, Massachusetts.

About Perspective Therapeutics

Perspective Therapeutics, Inc., together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma. Perspective Therapeutics, Inc. has a clinical trial collaboration agreement with Bristol Myers Squibb to evaluate the safety and tolerability of [212Pb] VMT01 in combination with nivolumab in patients with histologically confirmed melanoma and positive MC1R imaging scans. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 1998 and is headquartered in Seattle, Washington.